NCT02520752View on ClinicalTrials.gov

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 10, 2015

Primary Completion Date

January 30, 2017

Study Completion Date

September 12, 2017

Conditions
cMET-dysregulated Advanced Solid Tumors
Interventions
DRUG

INC280

DRUG

Midazolam

DRUG

Caffeine

Trial Locations (12)

1756

Novartis Investigative Site, Sofia

15706

Novartis Investigative Site, Santiago de Compostela

20089

Novartis Investigative Site, Rozzano

21034

Novartis Investigative Site, Dijon

30322

Emory University School of Medicine/Winship Cancer Institute SC-2, Atlanta

63110

Washington University School of Medicine, St Louis

69310

Novartis Investigative Site, Pierre-Bénite

DK-2100

Novartis Investigative Site, Copenhagen

08003

Novartis Investigative Site, Barcelona

08035

Novartis Investigative Site, Barcelona

W12 0HS

Novartis Investigative Site, London

M20 9BX

Novartis Investigative Site, Manchester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY